Yeast with increased butanol tolerance involving a multidrug efflux pump gene

• US 8,614,085 B2
• Filed: 02/24/2010
• Issued: 12/24/2013
• Est. Priority Date: 02/27/2009
• Status: Active Grant

• Current Assignee: Gevo Incorporated
• Original Assignee: Butamax(TM) Advanced Biofuels LLC (BP PLC)
• Inventors: Van Dyk, Tina K.
• Primary Examiner(s): RAMIREZ, DELIA M
• Application Number:
  US12/711,308
• Publication Number:
  US 20100221801A1
• Time in Patent Office: 1,399 Days
• Field of Search: 435/254.2, 435/69.1, 435/320, 435/160, 435/440, 530/350, 536/23.1
• US Class Current: 435/254.2
• CPC Class Codes: C12P 7/16 Butanols
• CPC Class Codes: Y02E 50/10 Biofuels, e.g. bio-diesel

Abstract

Increasing tolerance to butanol in yeast has been accomplished by decreasing activity of Pdr5p encoded by an endogenous PDR5 gene. A deletion mutation of the PDR5 gene led to improved growth yield in the presence of butanol. Yeast cells with reduced Pdr5p activity, or other multidrug resistance ATP-binding cassette transporter protein activity encoded by CDR1 or BFR1, and a butanol biosynthetic pathway may be used for improved butanol production.

Claims

1. A recombinant yeast cell comprising:

a) an isobutanol biosynthetic pathway, wherein the recombinant yeast cell comprises heterologous genes encoding an acetolactate synthase, an acetohydroxy acid isomeroreductase, an acetohydroxy acid dehydratase, a branched-chain keto acid decarboxylase, and a branched-chain alcohol dehydrogenase that perform the following substrate to product conversions;

i) pyruvate to acetolactate catalyzed by the acetolactate synthase,

ii) acetolactate to 2,3-dihydroxyisovalerate catalyzed by the acetohydroxy acid isomeroreductase,

iii) 2,3-dihydroxyisovalerate to α

-ketoisovalerate catalyzed by the acetohydroxy acid dehydratase,

iv) α

-ketoisovalerate to isobutyraldehyde catalyzed by the branched-chain keto acid decarboxylase,

v) isobutyraldehyde to isobutanol catalyzed by the branched-chain alcohol dehydrogenase; and

b) at least one genetic modification in an endogenous gene encoding a multidrug ATP-binding cassette transporter protein, wherein the multidrug ATP-binding cassette transporter protein has at least 95% sequence identity to SEQ ID NO;

50, 52, 54, 56, or 58, wherein the at least one genetic modification decreases activity of the endogenous multidrug resistance ATP-binding cassette transporter protein, and;

wherein the yeast cell has improved tolerance to isobutanol as compared to the corresponding yeast cell that lacks the at least one genetic modification of (b).

2. The yeast cell of claim 1 wherein the genetic modification substantially eliminates expression of the endogenous multidrug resistance ATP-binding cassette transporter protein.

3. A method for the production of isobutanol comprising growing the yeast cell of claim 1 under conditions wherein isobutanol is produced.

4. The method of claim 3, further comprising recovering the isobutanol.

5. A method for producing a recombinant yeast cell having increased tolerance to isobutanol comprising:

a) providing a recombinant yeast cell comprising an isobutanol biosynthetic pathway, wherein the recombinant yeast cell comprises heterologous genes encoding an acetolactate synthase, an acetohydroxy acid isomeroreductase, an acetohydroxy acid dehydratase, a branched-chain keto acid decarboxylase and a branched-chain alcohol dehydrogenase that perform the following substrate to product conversions;

i) pyruvate to acetolactate catalyzed by the acetolactate synthase,

ii) acetolactate to 2,3-dihydroxyisovalerate catalyzed by the acetohydroxy acid isomeroreductase,

iii 2,3-dihydroxyisovalerate to α

-ketoisovalerate catalyzed by the acetohydroxy acid dehydratase,

iv α

-ketoisovalerate to isobutyraldehyde catalyzed by the branched-chain keto acid decarboxylase,

v isobutyraldehyde to isobutanol catalyzed by the branched-chain alcohol dehydrogenase; and

b) engineering the yeast cell of (a) to comprise at least one genetic modification in an endogenous gene encoding a multidrug ATP-binding cassette transporter protein, wherein the multidrug ATP-binding cassette transporter protein has at least 95% sequence identity to SEQ ID NO;

50, 52, 54 56, or 58, wherein the at least one genetic modification decreases activity of the multidrug resistance ATP-binding cassette transporter protein, and wherein the yeast cell has improved tolerance to isobutanol as compared to the corresponding yeast cell that lacks the at least one genetic modification.